The Cyprus IP Box for pharma, biotech & life sciences
Patents, orphan-drug designations, SPCs and other protected life-sciences IP qualify for the Cyprus IP Box, so companies that own and develop this IP can tax qualifying profit at an effective rate as low as ~3% in 2026.
Why pharma & biotech companies qualify
The Cyprus IP Box covers patents, utility models, orphan-drug designations, plant-breeder and genetic IP, and supplementary protection certificates (SPCs). Income earned during a patent's life, an orphan drug's market-exclusivity period, or an SPC extension is qualifying IP income. As always, the benefit follows the R&D you fund yourself or outsource to unrelated parties.
- Patents, SPCs, orphan-drug designations and genetic/plant IP qualify.
- Income during exclusivity and SPC-extension periods qualifies.
- In-house or unrelated-party R&D maximises the nexus ratio.
- Capital gains on the disposal of qualifying IP are tax-exempt.
Effective tax rate for an owner-developed SaaS
~3%
15% corporate tax on just 20% of qualifying profit (2026).
Estimate your rate →Which life-sciences income qualifies
Income from your qualifying patented and protected IP, less the direct costs of earning it.
Royalties & licence fees
Payments to use your patents, formulations or processes.
IP embedded in product price
The share of a product's price reflecting your patented IP.
Gains on IP disposal
Capital gains from selling qualifying IP are fully exempt.
Pure resale or unrelated trading income does not qualify, and marketing IP (brands, trademarks) is always excluded.
Built for life sciences
Pharma & drug development
APIs, formulations, methods of use and orphan drugs.
Biotech & genetics
Genetic material, plant-variety rights and bio-processes.
Medical devices
Patented devices and the software embedded in them.
Diagnostics & healthtech
Proprietary diagnostics and protected healthtech IP.
Patents, SPCs and orphan-drug exclusivity
Yes. Patents and their statutory extensions are qualifying assets for the Cyprus IP Box, and life-sciences companies can benefit across the full protected life of a medicine. A granted patent on an active pharmaceutical ingredient, formulation, manufacturing process or medical device is exactly the kind of legally protected asset the IP Box rewards, so the profit attributable to it is eligible for the 80% notional deduction.
The value of a pharmaceutical patent rarely stops at the standard 20-year term. Because so much of that term is consumed by clinical trials and regulatory review, the EU allows a Supplementary Protection Certificate (SPC) to extend patent protection on an approved product for up to five further years. Income earned during the life of an SPC continues to qualify for the Cyprus IP Box, so the preferential treatment tracks the extended monopoly rather than ending at nominal patent expiry.
Orphan-drug designations follow the same logic. A designation granted for a treatment addressing a rare disease qualifies as protected IP, and income earned during the period of EU market exclusivity (typically ten years) qualifies for the IP Box. In practice this means a rare-disease developer can shelter the bulk of its commercial return under a regime aligned with the OECD nexus approach.
- Patents on APIs, formulations, processes and devices qualify.
- SPCs extend patent protection on approved products; income during the SPC qualifies.
- Orphan-drug designations qualify, and income during the period of EU market exclusivity qualifies.
Which life-sciences income qualifies
Most commercial income streams a life-sciences business generates from its protected IP can enter the Cyprus IP Box. The three principal categories are royalties and licence fees received for allowing others to use the IP, the IP-related portion of income embedded in the price of a product sold or manufactured, and capital gains on the disposal of the qualifying IP itself, which are treated as 0% and fall outside the IP Box calculation entirely.
The embedded-IP route matters most to product companies. When a patented medicine, diagnostic or device is sold, part of the sale price reflects the underlying protected IP; that portion is treated as qualifying income even though no separate licence exists. This lets integrated manufacturers, not just pure licensors, access the regime.
A worked example shows the effect. Assume €1,000,000 of qualifying profit from a patented product and a nexus ratio of 100%. The 80% notional deduction removes €800,000, leaving €200,000 taxable. At the 2026 corporate rate of 15%, tax due is €30,000 which is an effective rate of 3% on the IP profit.
- Royalties and licence fees for use of the IP.
- The IP-related portion of income embedded in a product's sale or manufacturing price.
- Capital gains on disposal of the qualifying IP, taxed at 0%.
- Worked example: €1,000,000 profit x 100% nexus, 80% deduction leaves €200,000; tax at 15% = €30,000 = 3%.
Clinical & outsourced R&D and your nexus ratio
Your nexus ratio measures how much of the qualifying IP you developed through your own R&D effort, and it directly scales the benefit. In-house R&D counts in full, and, crucially for life sciences, so does R&D outsourced to unrelated third parties such as a contract research organisation (CRO), even when that CRO performs the work abroad. Since pharma and biotech typically run trials and preclinical work through external CROs, this treatment protects the ratio for most developers.
Two things reduce the nexus ratio: R&D outsourced to related parties within your own group, and IP acquired from others rather than developed. These costs sit in the denominator but not the qualifying numerator, so heavy reliance on intra-group R&D or bought-in IP dilutes the benefit.
To soften this, the OECD nexus framework allows a 30% uplift. Qualifying expenditure can be increased by 30% (capped at total expenditure) to partly offset acquisition and related-party costs, so a business that has done substantial genuine R&D can often still reach or approach a 100% ratio.
- In-house R&D and unrelated-party CRO work qualify, including work performed abroad.
- Related-party R&D and acquired IP lower the ratio.
- A 30% uplift on qualifying expenditure (capped at total cost) partly offsets those costs.
Documentation for life-sciences IP
Robust documentation is what converts eligibility into a defensible claim, and life-sciences IP demands more of it than most sectors because development is long, multi-party and heavily regulated. The core requirement is to evidence the full development history of each asset and to show who performed the R&D, so that the nexus ratio can be reconstructed if challenged.
Costs must be tracked on a per-asset basis. The nexus calculation is done asset by asset, so you need to attribute qualifying and non-qualifying expenditure to each specific patent, SPC or orphan-drug programme rather than pooling R&D spend across the pipeline.
Because much of the value rests in regulatory and scientific records, trial and lab documentation should be retained as supporting evidence. Keeping this contemporaneously, rather than reconstructing it later, is the single biggest factor in surviving a review of a Cyprus IP Box claim.
- Full development history for each qualifying asset.
- Records of who performed the R&D, in-house and via each CRO.
- Per-asset cost tracking splitting qualifying from non-qualifying spend.
- Trial and lab records retained as contemporaneous supporting evidence.
Pharma & biotech FAQ
Talk to a Cyprus IP Box specialist.
Book a free, no-obligation assessment. We'll confirm whether you qualify, estimate your effective rate, and give you a fixed quote — confidentially, usually within one business day.
Reviewed by a Cyprus-admitted advocate · Last updated 21 June 2026.